Status:

UNKNOWN

Neurogenic Myocardial and Lung Injury in SAH Patients

Lead Sponsor:

Medical University of Silesia

Conditions:

Myocardial Injury

Lung Injury

Eligibility:

All Genders

18+ years

Brief Summary

Up to this day, little is known whether the extent of brain damage in patients with SAH correlates with the degree neurogenic myocardial injury and neurogenic lung injury. This is a prospective obser...

Detailed Description

Multiple forms of brain damage, primarily, subarachnoid haemorrhage (SAH) are frequently accompanied by neurogenic myocardial injury with changes in the electrocardiogram, accompanied by the release o...

Eligibility Criteria

Inclusion

  • patients with subarachnoid haemorrhage (both aneurysmal and non-aneurysmal) with acute consciousness disturbances (Glasgow Coma Scale \< 8 pts) requiring intubation and mechanical ventilation, hospitalized in the ICU for over 24 hours

Exclusion

  • severe prior pulmonary diseases
  • severe prior cardiac diseases
  • death in the first 72 hours of ICU stay
  • need for any extracorporeal life-saving techniques

Key Trial Info

Start Date :

January 22 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2024

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT05408988

Start Date

January 22 2022

End Date

December 31 2024

Last Update

May 6 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Clinical Center prof. K. Gibiński of the Medical University of Silesia in Katowice

Katowice, Silesian Voivodeship, Poland, 40-752